David T. Rubin MD, FACG, AGAF, FACP, FASGEProfessor of Medicine at University of Chicago
Miguel D. Regueiro MD, FACGProfessor of Medicine Lerner College of Medicine, Cleveland
The agenda for this live webinar includes two 35-minutes presentations and a 15-minute panel discussion with Prof. David T. Rubin and Prof. Miguel D. Regueiro.
20:00 - 20:05: Opening and Introduction
20:05 - 20:40: Lecture 1 - Personalizing Treatment Algorithm in CD
20:40 - 21:15: Lecture 2 - Stopping UC Progression in its Tract to Optimize Care
21:15 - 21:30: Panel Discussion
Crohn’s disease (CD) follows a relapsing and remitting course that typically results in progressive bowel damage. The appreciation that CD is a progressive disease has led to earlier treatment with biologics within a window of opportunity in order to halt disease progression.
It is unknown whether ulcerative colitis (UC) has the same natural history of progression to irreversible bowel damage as does CD, and much less whether an earlier, more aggressive treatment could alter this tendency. There is therefore a tendency for physicians to consider UC a less progressive disease, resulting in a hesitancy to initiate more potent treatments earlier in the disease course, even if this approach has been shown to have better outcomes.
There is evidence in the literature that UC is also a progressive disease. Progressing by extending proximally and, like CD, may also be complicated by structural and functional damage beyond the mucosal layer, leading to strictures, pseudopolyposis, bridging fibrosis, dysmotility, anorectal incontinence, and possibly impaired permeability.
Treatment approaches for disease categorized as mild, moderate, or severe have most often been based on a current assessment of symptoms or disease activity without including a longitudinal assessment of a patient’s disease course including past disease complications and surgeries.
In addition, since not all patients will progress to a complicated disease course, it is therefore important to take into consideration the risks of disease progression and prognosis.
In both presentations, we will look at the State-of-the-Art management strategy of IBD that involves considerations surrounding disease activity vs severity, risk stratification, when and how to choose the best first advanced therapy for IBD patients.
Prof. David T. Rubin is Chief of the Section of Gastroenterology, Hepatology & Nutrition and the Co-Director of the Digestive Diseases Center at The University of Chicago Medicine. Dr. Rubin earned a medical degree with honors at The University of Chicago Pritzker School of Medicine. He completed his residency in internal medicine and fellowships in gastroenterology and clinical medical ethics at the University of Chicago, where he served as Chief Resident and Chief Fellow. Prior to his current appointments, Dr. Rubin served for 11 years as Director of the Gastroenterology, Hepatology and Nutrition fellowship program. He also currently serves as an associate faculty member at the MacLean Center for Clinical Medical Ethics and an associate investigator at the University of Chicago Comprehensive Cancer Center.
Prof. Rubin is a Fellow of the American Gastroenterological Association (AGA), the American College of Gastroenterology (ACG), the American Society for Gastrointestinal Endoscopy (ASGE) and the American College of Physicians (ACP) and an active national member of the Crohn’s & Colitis Foundation (CCF), and is on the Board of Trustees for the ACG. Among numerous awards and honors, Dr. Rubin was chosen by his peers as a member of Best Doctors (recognized for superior clinical ability) and America’s Top Physicians (gastroenterology). Additionally, he twice received the ACG’s Governor’s Award of Excellence in Clinical Research (2003 and 2013), the Cancer Research Foundation Young Investigator’s Award (2004), and the UC Postgraduate Teaching Award in recognition of significant contributions for fellowship education (2006). In 2012, he received the CCF Rosenthal Award, a national leadership award bestowed upon a volunteer who has contributed in an indisputable way to the quality of life of patients and families. He is currently the Chair-elect of the National Scientific Advisory Committee of the CCF. He is an Associate Editor of the journal Gastroenterology and Co-Editor of the ACG On-Line Educational Universe.
Prof. Miguel D. Regueiro is the Chair of the Department of Gastroenterology and Hepatology and Vice Chair of the Digestive Disease and Surgery Institute at Cleveland Clinic in Ohio. He serves as Medical Co-Chair of Digestive Disease and Surgical Institute Research Governance committee and is Professor of Medicine at the Lerner College of Medicine.
Prof. Regueiro was Professor of Medicine and Clinical and Translational Science at the University of Pittsburgh School of Medicine from 2000 to 2018. There he served as the IBD Clinical Medical Director, Associate Chief for Education, and was the former Director of the Gastroenterology, Hepatology, and Nutrition Fellowship Training Program. He was Senior Medical Lead of Specialty Medical Homes and was appointed Professor with Tenure and honored as the UPMC Endowed Chair, Patient Centered Care in Inflammatory Bowel Diseases.
Prof. Regueiro’s main clinical and research interest is inflammatory bowel disease (IBD), with a focus on the natural course of these diseases and postoperative prevention of Crohn’s disease. He has been instrumental in researching methods of prevention of postoperative Crohn’s disease and has led national and international research in the field. Due to his work, clinical pathways, guidelines, and algorithms of postoperative Crohn’s disease have been created. Recently, he has been involved in developing new models of healthcare, including the first-of-its kind specialty medical home for IBD.
To access this presentation, please login and click on the 'ENROLL TO WATCH' blue button by the right, on this page. To create a new account, please click here.